Bartholomeeusen K, Daniel M, LaBeaud D, Gasque P, Peeling R, Stephenson K
Nat Rev Dis Primers. 2023; 9(1):17.
PMID: 37024497
PMC: 11126297.
DOI: 10.1038/s41572-023-00429-2.
Babaeimarzangou S, Zaker H, Soleimannezhadbari E, Gamchi N, Kazeminia M, Tarighi S
Exp Ther Med. 2022; 25(1):42.
PMID: 36569444
PMC: 9768462.
DOI: 10.3892/etm.2022.11741.
Srivastava P, Kumar A, Hasan A, Mehta D, Kumar R, Sharma C
Front Immunol. 2020; 11:695.
PMID: 32411133
PMC: 7198842.
DOI: 10.3389/fimmu.2020.00695.
Schrauf S, Tschismarov R, Tauber E, Ramsauer K
Front Immunol. 2020; 11:592.
PMID: 32373111
PMC: 7179680.
DOI: 10.3389/fimmu.2020.00592.
Reyes-Sandoval A
Hum Vaccin Immunother. 2019; 15(10):2351-2358.
PMID: 30735447
PMC: 6816471.
DOI: 10.1080/21645515.2019.1574149.
Vaccine and Therapeutic Options To Control Chikungunya Virus.
Powers A
Clin Microbiol Rev. 2017; 31(1).
PMID: 29237708
PMC: 5740971.
DOI: 10.1128/CMR.00104-16.
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure A, Berkowitz N, Graham B, Ledgerwood J
J Infect Dis. 2016; 214(suppl 5):S497-S499.
PMID: 27920180
PMC: 5137244.
DOI: 10.1093/infdis/jiw352.
Chikungunya vaccines in development.
Schwameis M, Buchtele N, Wadowski P, Schoergenhofer C, Jilma B
Hum Vaccin Immunother. 2015; 12(3):716-31.
PMID: 26554522
PMC: 4964651.
DOI: 10.1080/21645515.2015.1101197.
Nonhuman Primate Models of Chikungunya Virus Infection and Disease (CHIKV NHP Model).
Broeckel R, Haese N, Messaoudi I, Streblow D
Pathogens. 2015; 4(3):662-81.
PMID: 26389957
PMC: 4584280.
DOI: 10.3390/pathogens4030662.
Antiviral perspectives for chikungunya virus.
Parashar D, Cherian S
Biomed Res Int. 2014; 2014:631642.
PMID: 24955364
PMC: 4052087.
DOI: 10.1155/2014/631642.
Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein.
Kam Y, Lum F, Teo T, Lee W, Simarmata D, Harjanto S
EMBO Mol Med. 2012; 4(4):330-43.
PMID: 22389221
PMC: 3376860.
DOI: 10.1002/emmm.201200213.
A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis.
Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M
Vaccine. 2011; 29(15):2803-9.
PMID: 21320541
PMC: 3061842.
DOI: 10.1016/j.vaccine.2011.01.108.
A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection.
Akahata W, Yang Z, Andersen H, Sun S, Holdaway H, Kong W
Nat Med. 2010; 16(3):334-8.
PMID: 20111039
PMC: 2834826.
DOI: 10.1038/nm.2105.
Replication cycle of chikungunya: a re-emerging arbovirus.
Solignat M, Gay B, Higgs S, Briant L, Devaux C
Virology. 2009; 393(2):183-97.
PMID: 19732931
PMC: 2915564.
DOI: 10.1016/j.virol.2009.07.024.
Cross-protection in hamsters immunized with group A arbovirus vaccines.
COLE Jr F, MCKINNEY R
Infect Immun. 1971; 4(1):37-43.
PMID: 5154876
PMC: 416261.
DOI: 10.1128/iai.4.1.37-43.1971.
Chikungunya virus vaccine prepared by Tween-ether extraction.
Eckels K, HARRISON V, Hetrick F
Appl Microbiol. 1970; 19(2):321-5.
PMID: 4985431
PMC: 376676.
DOI: 10.1128/am.19.2.321-325.1970.
Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures.
White A, Berman S, Lowenthal J
Appl Microbiol. 1972; 23(5):951-2.
PMID: 4624213
PMC: 380477.
DOI: 10.1128/am.23.5.951-952.1972.
Immunogenicity of purified, inactivated chikungunya virus in monkeys.
Nakao E, Hotta S
Bull World Health Organ. 1973; 48(5):559-62.
PMID: 4204490
PMC: 2482923.
